Clinical trials
Breast clinical trials
Below are recruiting breast clinical trials, each written for real people, not researchers. We’re tracking 2,691 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05576389RecruitingPhase 2
Fluzoparib plus camrelizumab before surgery for BRCA-related HER2-negative breast cancer
This study tests a combination of two drugs – fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy) – given before surgery for early-stage or locally advanced HER2-negative breast cancer in people with an inherited BRCA mutation. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06857305Enrolling by invitationPhase 3
Eribulin every two weeks vs standard schedule for advanced breast cancer
This trial compares a new every-two-week dosing schedule of the chemotherapy drug eribulin to the standard schedule in people with HER2-negative breast cancer that has returned or spread. The goal is to see if the biweekly regimen is safer or works better.
Beijing, BAges 18 years+ - NCT07630402Recruiting
Heart Imaging Study for Women With Early Breast Cancer
This study helps doctors find the best way to monitor heart health in women with HER2-positive breast cancer who are receiving a type of targeted chemotherapy. The goal is to catch any heart problems early and keep you safe during treatment.
Rochester, New YorkAges 18–79 - NCT05983107RecruitingPhase 2
Chidamide/Everolimus for advanced breast cancer
This trial tests a combination of two drugs, chidamide and everolimus, for people with advanced HR+/HER2- breast cancer. It aims to see if the combination works for tumors with or without a PIK3CA gene mutation. You may be able to join if you've had previous treatment with CDK4/6 inhibitors and up to two prior chemotherapies.
Beijing, Beijing MunicipalityAges 18–75 - NCT06797258Recruiting
FlexHD for Breast Reconstruction After Mastectomy
This study tests a special type of tissue support (FlexHD Pliable) used during breast reconstruction right after a mastectomy. It may help women who want implants placed above the chest muscle.
Fort Worth, TexasAges 22 years+ - NCT06839547Recruiting
Testing a new drug with radiation for advanced breast cancer brain tumors
This study looks at how well a new anti-tumor drug works when given along with radiation therapy for people whose advanced breast cancer has spread to the brain. It may help the radiation work better and control the cancer longer.
BeijingAges 18 years+ - NCT07635342RecruitingPhase 2
Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
Shijiazhuang, HebeiAges 18–65 - NCT07284836RecruitingPhase 2
Chemo directly to liver for breast cancer
This trial tests a new way to give chemotherapy directly to the liver for breast cancer that has spread only there. It's for people who have already tried two or more standard treatments.
Hangzhou, ZhejiangAges 18–70 - NCT06827613RecruitingPhase 1/Phase 2
Study of invikafusp alfa plus sacituzumab govitecan for advanced solid tumors
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07067710Recruiting
Imagery and movement study for breast cancer survivors
This study tests if visualizing and watching movements can help improve strength, motion, pain, and fear of movement in women who finished breast cancer treatment. It focuses on those with arm issues like pain, limited movement, or lymphedema.
Pamplona, NavarreAges 18 years+ - NCT06860529RecruitingPhase 2
Immunotherapy plus chemo for early-stage HR+/HER2- breast cancer
This trial tests adding the immunotherapy drug serplulimab to standard chemotherapy for people with early-stage HR-positive, HER2-negative breast cancer. It aims to see if this combination can improve outcomes before surgery.
Zhengzhou, HenanAges 18 years+ - NCT06575192RecruitingPhase 3
Breast reconstruction study with ARTIA matrix
This study tests a new supportive mesh called ARTIA for women having breast reconstruction immediately after a mastectomy. The mesh is placed under the skin to help hold a breast implant in position during a two-stage reconstruction process.
Los Angeles, CaliforniaAges 18 years+ - NCT07263425RecruitingPhase 2
Study of thiotepa and trastuzumab for breast cancer that spread to the lining of the brain and spinal cord
This trial tests a combination of two drugs given through a special port in the head to treat HER2-positive breast cancer that has spread to the layer covering the brain and spinal cord (leptomeningeal metastasis). It aims to see if this treatment is safe and effective.
Nanjing, JiangsuAges 18–75 - NCT06731140RecruitingPhase 2
Reversing immune resistance in HER2-negative breast cancer
This trial tests a new treatment to see if it can reverse resistance to immunotherapy in people with HER2-negative breast cancer. It's for patients whose cancer has gotten worse after immunotherapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06771609RecruitingPhase 2
Immunotherapy plus low-dose chemo for advanced triple-negative breast cancer
This study tests a combination of an immunotherapy drug (PD-L1 inhibitor) with a special low-dose chemotherapy regimen (VEX) plus optional radiation for advanced triple-negative breast cancer. The goal is to see if this approach works better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05759546RecruitingPhase 2
Test a PARP and CDK4/6 medicine plus hormone therapy
This Phase 2 study tests whether combining a PARP inhibitor with a CDK4/6 inhibitor and hormone (endocrine) therapy can help people with advanced HR-positive, HER2-negative breast cancer. It’s for certain patients who have not yet had chemotherapy or targeted therapy for metastatic disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05890287Recruiting
Chidamide plus hormone therapy after chemotherapy for breast cancer
This trial studies chidamide added to standard hormone (endocrine) therapy to help prevent breast cancer from coming back after initial chemotherapy. It may help by keeping cancer under control for longer in people with HR-positive, HER2-negative breast cancer who respond to first-line treatment.
TianjinAges 18–75 - NCT06876610Recruiting
Blood test for early breast cancer detection
This trial tests a blood test that looks for chemical changes in DNA to help diagnose breast cancer. It may offer a simpler way to detect cancer without needing a tissue sample.
Beijing, Beijing MunicipalityAges 30–75 - NCT06934239RecruitingPhase 4
AI-assisted vs. standard mammograms for breast cancer screening
This trial compares standard mammograms with mammograms aided by artificial intelligence (AI) to see if AI helps find breast cancer more accurately and reduces unnecessary callbacks. If you're 18 or older and getting a routine screening mammogram at one of the six participating health systems, you may be eligible.
Los Angeles, CaliforniaAges 18 years+ - NCT06722612Recruiting
Chemo plus targeted therapy for high-risk HER2+ early breast cancer
This trial tests whether combining chemotherapy with targeted therapy works better for women with high-risk, HER2 positive early breast cancer that hasn't spread to lymph nodes. If you've had surgery and your tumor fits certain high-risk features, you may be eligible to join.
Beijing, Beijing MunicipalityAges Any age - NCT06919042Recruiting
Shockwave therapy for breast reconstruction scar tissue
This trial tests if a special shockwave treatment can soften firm scar tissue that sometimes forms after breast reconstruction surgery. If you've had plastic surgery and have firm, tight areas under your skin, this study might be able to help.
Chicago, IllinoisAges 18 years+ - NCT06938399Recruiting
Motiva Breast Implants Safety Study
This study follows women who receive Motiva silicone breast implants for either a first-time augmentation or a replacement of previous implants. It will track safety and outcomes over time to confirm the implants work well.
Beverly Hills, CaliforniaAges 22 years+ - NCT05861830RecruitingPhase 3
Dalpiciclib plus hormone therapy after CDK4/6 treatment
This trial tests dalpiciclib together with hormone (endocrine) therapy in people with HR-positive, HER2-negative advanced breast cancer whose cancer has already responded poorly to a prior CDK4/6 inhibitor. It aims to see if this combination can better control the cancer after that earlier treatment has failed.
Beijing, Beijing MunicipalityAges 18–80 - NCT06531135Enrolling by invitation
Counseling to help you adjust to breast cancer
This trial tests a counseling program to help people with breast cancer feel more positive and cope better. It's designed for newly diagnosed patients who can read and write Chinese.
TaipeiAges 20–70
Hear when a new Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast?
- Yes. Clin2 currently lists 2,691 recruiting breast studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.